SecBot SecBot
PRESS-RELEASE ·Filed Mar 13, 2026

LFWD

Lifeward Ltd.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ◆ Mixed

Monitor for transaction closing and initial funding tranches; assess whether capital inflows reduce near-term dilution risk given LFWD's $10M market cap. Watch for updates on integration of POD™ tech and any shift in R&D focus away from core MedTech.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.85
T+0 close · Mar 13, 2026 · via day close
Latest settled
+1.90%
T+60 · $6.98
Vs SPY
−9.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 13 $6.85entry
  2. T+1 · 8mo ago +7.88%α +6.86% · $7.39
  3. T+5 · 8mo ago −1.61%α +0.51% · $6.74
  4. T+20 · 7mo ago −5.11%α −8.70% · $6.50
  5. T+60 · 5mo ago +1.90%α −9.72% · $6.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifeward announced shareholder approval of a strategic partnership with Oramed Pharmaceuticals, integrating Oramed’s POD™ oral delivery technology into Lifeward’s platform while receiving potential access to up to $47 million in capital. Oramed will fund clinical development of the biotech platform, allowing Lifeward to maintain focus on its core MedTech business and path to profitability.

Key Financial Metrics

Deal Value
$47.0M

Key Facts

  • Shareholders approved the issuance of shares related to the strategic partnership with Oramed Pharmaceuticals (Nasdaq: ORMP).
  • Lifeward gains access to Oramed’s POD™ oral delivery technology for biologics, with potential applications in diabetes and other chronic diseases.
  • Oramed will fund and manage the clinical development of the POD™ platform under a trial management agreement.
  • Lifeward could receive up to $47 million in capital via equity, convertible notes, milestone payments, and warrants from Oramed and another investor.
  • Transaction remains subject to customary closing conditions.

Financial Impact

Up to $47 million in potential capital from Oramed and another investor through multiple instruments

cashdilutionstrategic assetsR&D exposure

Risk Factors

  • Execution risk in integrating biotech platform while maintaining focus on core MedTech profitability.
  • Potential shareholder dilution from issuance of ordinary shares and prefunded warrants.
  • Dependency on Oramed for clinical funding and development timelines.
  • Forward-looking statements dominate; actual capital inflows are not guaranteed.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3255419

Track record

25 reports on LFWD

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +20.27% at T+60 after the Aug 14, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Bearish 6/10 Entry $4.06 Now $3.62 +10.84% settles Nov 20
  2. Nov 12, 20264d ago 3 Neutral 1/10 Entry $4.06 Now $3.62 −10.84% settles Nov 20
  3. Nov 3, 202613d ago 3 Neutral 2/10 Entry $6.06 to $5.76 Now $3.62 −40.26% ▼ −4.95% −4.04% vs SPY
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $6.04 to $5.83 Now $3.62 −40.07% ▼ −3.48% −1.49% vs SPY
  5. Oct 8, 20265w ago 8-K Bearish 5/10 Entry $6.49 to $6.00 Now $3.62 +44.22% ▲ +7.55% +5.58% vs SPY
  6. Oct 1, 20266w ago 8-K Neutral 2/10 Entry $5.96 to $6.43 Now $3.62 −39.26% ▲ +7.89% +6.58% vs SPY
  7. Sep 25, 20267w ago DEF 14A Bearish 7/10 Entry $6.92 to $6.67 Now $3.62 +47.69% ▲ +3.61% +4.82% vs SPY
  8. Aug 14, 202613w ago 8-K Mixed 6/10 No price data
  9. Aug 14, 202613w ago Press Release Bearish 6/10 Entry $7.45 to $7.32 Now $3.62 +51.41% ▲ +1.75% +0.38% vs SPY
  10. Aug 11, 202614w ago EFFECT Bearish 7/10 Entry $7.57 to $7.41 Now $3.62 +52.15% ▲ +2.08% +1.67% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 13, 2026